1
|
Response of human melanoma cell lines to interferon-beta gene transfer mediated by a modified adenoviral vector. Sci Rep 2020; 10:17893. [PMID: 33087767 PMCID: PMC7578831 DOI: 10.1038/s41598-020-74826-y] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2020] [Accepted: 09/25/2020] [Indexed: 01/08/2023] Open
Abstract
Since melanomas often retain wild type p53, we developed an adenoviral vector, AdRGD-PG, which provides robust transduction and transgene expression in response to p53. Previously, this vector was used for interferon-β gene transfer in mouse models of melanoma, resulting in control of tumor progression, but limited cell killing. Here, the AdRGD-PG-hIFNβ vector encoding the human interferon-β cDNA (hIFNβ) was used to transduce human melanoma cell lines SK-MEL-05 and SK-MEL-147 (both wild type p53). In vitro, cell death was induced in more than 80% of the cells and correlated with elevated annexinV staining and caspase 3/7 activity. Treatment with hIFNβ promoted cell killing in neighboring, non-transduced cells, thus revealing a bystander effect. In situ gene therapy resulted in complete inhibition of tumor progression for SK-MEL-147 when using nude mice with no evidence of hepatotoxicity. However, the response in Nod-Scid mice was less robust. For SK-MEL-05, tumor inhibition was similar in nude and Nod-Scid mice and was less efficient than seen for SK-MEL-147, indicating both cell type and host specific responses. The AdRGD-PG-hIFNβ vector provides extensive killing of human melanoma cells in vitro and a potent anti-tumor effect in vivo. This study provides a critical advance in the development of our melanoma gene therapy approach.
Collapse
|
2
|
Ferreira LM, Cervi VF, Sari MHM, Barbieri AV, Ramos AP, Copetti PM, de Brum GF, Nascimento K, Nadal JM, Farago PV, Sagrillo MR, Nogueira CW, Cruz L. Diphenyl diselenide loaded poly(ε-caprolactone) nanocapsules with selective antimelanoma activity: Development and cytotoxic evaluation. MATERIALS SCIENCE & ENGINEERING. C, MATERIALS FOR BIOLOGICAL APPLICATIONS 2018; 91:1-9. [DOI: 10.1016/j.msec.2018.05.014] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/20/2017] [Revised: 04/10/2018] [Accepted: 05/02/2018] [Indexed: 12/26/2022]
|
3
|
Kızılbey K, Mansuroğlu B, Derman S, Mustafaeva Akdeste Z. An In vivo study: Adjuvant activity of poly-n-vinyl-2-pyrrolidone-co-acrylic acid on immune responses against Melanoma synthetic peptide. Bioengineered 2018; 9:134-143. [PMID: 28910565 PMCID: PMC5972930 DOI: 10.1080/21655979.2017.1373529] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2017] [Revised: 07/10/2017] [Accepted: 07/10/2017] [Indexed: 11/23/2022] Open
Abstract
Peptides have been studied as an important class of components in medicine to control many major diseases with vaccination. Polymers as adjuvants are capable of enhancing the vaccine potential against various diseases by improving the delivery of antigens, and they reduce the booster doses of vaccines. In brief, polymers are promising candidates for peptide-based vaccine delivery platforms. The purpose of the present study was to create a possible alternative approach in the treatment of malignant melanoma and/or to prevent metastasis of melanoma. The study was designed as both an experimental and an in vivo study. We prepared a complex and covalent conjugate of MAGE-3 121-134 (L-L-K-Y-R-A-R-E-P-V-T-K-A-E) T-cell epitope as a vaccine candidate for melanoma. These conjugates were able to generate an immune response in mice after a single immunization, without the help of any external adjuvant. The peptide-polymer complexes activated the immune system in the best way and formed the highest antigen specific immune response. These results indicate the adjuvant activity of Poly(N-vinyl-2- pyrrolidone-co-acrylic acid) [P(VP-co-AA)] and the potential use of P(VP-coAA)-peptide based vaccine prototypes for future melanoma cancer vaccine formulations.
Collapse
MESH Headings
- Acrylic Resins/administration & dosage
- Acrylic Resins/chemistry
- Adjuvants, Immunologic/administration & dosage
- Adjuvants, Immunologic/chemistry
- Amino Acid Sequence
- Animals
- Antibodies, Neoplasm/blood
- Antigens, Neoplasm/chemistry
- Antigens, Neoplasm/immunology
- Cancer Vaccines/administration & dosage
- Cancer Vaccines/chemistry
- Cancer Vaccines/immunology
- Epitopes, T-Lymphocyte/administration & dosage
- Epitopes, T-Lymphocyte/chemistry
- Epitopes, T-Lymphocyte/immunology
- Humans
- Immunity, Humoral/drug effects
- Immunization, Secondary
- Immunoconjugates/administration & dosage
- Immunoconjugates/chemistry
- Male
- Melanoma/blood
- Melanoma/immunology
- Melanoma/pathology
- Melanoma/prevention & control
- Mice
- Mice, Inbred BALB C
- Neoplasm Proteins/chemistry
- Neoplasm Proteins/immunology
- Peptides/administration & dosage
- Peptides/chemistry
- Peptides/immunology
- Povidone/administration & dosage
- Povidone/analogs & derivatives
- Povidone/chemistry
- Serum Albumin, Bovine/administration & dosage
- Serum Albumin, Bovine/chemistry
- Serum Albumin, Bovine/immunology
- Skin Neoplasms/blood
- Skin Neoplasms/immunology
- Skin Neoplasms/pathology
- Skin Neoplasms/prevention & control
- T-Lymphocytes/chemistry
- T-Lymphocytes/drug effects
- T-Lymphocytes/immunology
- Vaccination
- Vaccines, Subunit
- Melanoma, Cutaneous Malignant
Collapse
Affiliation(s)
- Kadriye Kızılbey
- Biomedical Engineering Department, İstanbul Yeni Yüzyıl University, Yılanlı Ayazma Caddesi, Zeytinburnu-İstanbul, Turkey
| | - Banu Mansuroğlu
- Department of Molecular Biology and Genetics, Yıldız Technical University, Davutpaşa Caddesi, Esenler, İstanbul, Turkey
| | - Serap Derman
- Department of Bioengineering, Yıldız Technical University, Davutpaşa Caddesi, Esenler, İstanbul, Turkey
| | - Zeynep Mustafaeva Akdeste
- Department of Bioengineering, Yıldız Technical University, Davutpaşa Caddesi, Esenler, İstanbul, Turkey
| |
Collapse
|
4
|
Rigon RB, Oyafuso MH, Fujimura AT, Gonçalez ML, do Prado AH, Gremião MPD, Chorilli M. Nanotechnology-Based Drug Delivery Systems for Melanoma Antitumoral Therapy: A Review. BIOMED RESEARCH INTERNATIONAL 2015; 2015:841817. [PMID: 26078967 PMCID: PMC4442269 DOI: 10.1155/2015/841817] [Citation(s) in RCA: 49] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/09/2015] [Revised: 04/06/2015] [Accepted: 04/07/2015] [Indexed: 12/11/2022]
Abstract
Melanoma (MEL) is a less common type of skin cancer, but it is more aggressive with a high mortality rate. The World Cancer Research Fund International (GLOBOCAN 2012) estimates that there were 230,000 new cases of MEL in the world in 2012. Conventional MEL treatment includes surgery and chemotherapy, but many of the chemotherapeutic agents used present undesirable properties. Drug delivery systems are an alternative strategy by which to carry antineoplastic agents. Encapsulated drugs are advantageous due to such properties as high stability, better bioavailability, controlled drug release, a long blood circulation time, selective organ or tissue distribution, a lower total required dose, and minimal toxic side effects. This review of scientific research supports applying a nanotechnology-based drug delivery system for MEL therapy.
Collapse
Affiliation(s)
- Roberta Balansin Rigon
- School of Pharmaceutical Sciences, Department of Drug and Medicines, São Paulo State University, 14801-902 Araraquara, SP, Brazil
| | - Márcia Helena Oyafuso
- School of Pharmaceutical Sciences, Department of Drug and Medicines, São Paulo State University, 14801-902 Araraquara, SP, Brazil
| | - Andressa Terumi Fujimura
- School of Pharmaceutical Sciences, Department of Drug and Medicines, São Paulo State University, 14801-902 Araraquara, SP, Brazil
| | - Maíra Lima Gonçalez
- School of Pharmaceutical Sciences, Department of Drug and Medicines, São Paulo State University, 14801-902 Araraquara, SP, Brazil
| | - Alice Haddad do Prado
- School of Pharmaceutical Sciences, Department of Drug and Medicines, São Paulo State University, 14801-902 Araraquara, SP, Brazil
| | - Maria Palmira Daflon Gremião
- School of Pharmaceutical Sciences, Department of Drug and Medicines, São Paulo State University, 14801-902 Araraquara, SP, Brazil
| | - Marlus Chorilli
- School of Pharmaceutical Sciences, Department of Drug and Medicines, São Paulo State University, 14801-902 Araraquara, SP, Brazil
| |
Collapse
|
5
|
Effects of oral levamisole as an adjuvant to hepatitis B vaccine in adults with end-stage renal disease: a meta-analysis of controlled clinical trials. Clin Ther 2010; 32:1-10. [PMID: 20171406 DOI: 10.1016/j.clinthera.2010.01.005] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/04/2009] [Indexed: 12/14/2022]
Abstract
BACKGROUND Many patients receiving long-term dialysis do not produce protective antibodies to hepatitis B virus (HBV) surface antigen (HBsAg) after HBV vaccination. The results from several studies have suggested benefit of oral levamisole as an adjuvant to HBV vaccination in patients with end-stage renal disease (ESRD). However, reliable information is still lacking. OBJECTIVE This meta-analysis assessed the efficacy and safety profile of oral levamisole as an adjuvant to HBV vaccine in patients with ESRD. METHODS This meta-analysis included prospective controlled clinical trials identified using literature searches of MEDLINE, SCOPUS, Institute for Scientific Information bibliographic database, and Cochrane Collaboration's Central Register of Controlled Clinical Trials for controlled clinical trials that weighted the seroprotection rate in patients with ESRD who received oral levamisole + HBV vaccine versus those who received the HBV vaccine alone (control). The fixed-effects Mantel-Haenszel model was applied with the heterogeneity and sensitivity analyses. The response rate, defined as the proportion of patients with seroprotective concentrations of antibodies to HBsAg (>10 mIU/mL) at completion and 6 to 10 months after completion of the HBV vaccine schedule, was the end point of interest and was also analyzed separately. For the tolerability assessment, studies that reported dose reduction, levamisole discontinuation, and their adverse effects including laboratory abnormalities were included. RESULTS The literature search identified 4 studies that fulfilled the inclusion criteria (328 patients). The mean ages of the patients in these studies ranged from 41 to 53 years, and sex distribution ranged from 52.6% to 68.0% male. Twenty-two patients received oral levamisole 100 mg/d for 12 days (from 6 days before to 6 days after each vaccination). A total of 106 patients received oral levamisole 80 to 120 mg for 4 to 6 months. Aggregation of study results suggested a significant increase in response rate in the group that received levamisole + HBV vaccine compared with the control group (pooled odds ratio [OR] = 2.77 [95% CI, 1.56-4.94]) after completion and 6 to 10 months after the vaccination period (pooled OR = 3.96 [95% CI, 1.71-9.18]). The test of heterogeneity was not statistically significant in either group. Five patients underwent dose reduction due to mild adverse events. In one trial, 3 patients died, 1 of whom was receiving levamisole; however, the authors did not provide the causes of death. No other serious adverse events were reported with levamisole administration. CONCLUSION The results from this meta-analysis suggest significant benefit in the administration of levamisole as an adjuvant to HBV vaccine to increase seroprotection in patients with ESRD.
Collapse
|
6
|
Mendenhall WM, Amdur RJ, Grobmyer SR, George TJ, Werning JW, Hochwald SN, Mendenhall NP. Adjuvant radiotherapy for cutaneous melanoma. Cancer 2008; 112:1189-96. [DOI: 10.1002/cncr.23306] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
7
|
Dréau D, Foster M, Hogg M, Culberson C, Nunes P, Wuthier RE. Inhibitory effects of fusarochromanone on melanoma growth. Anticancer Drugs 2007; 18:897-904. [PMID: 17667595 DOI: 10.1097/cad.0b013e3280d94298] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Fusarochromanone is a toxic metabolite produced by Fusarium equiseti, a fungus present in decaying cereal plants in northern latitudes; it has been detected in various food grains. Fusarochromanone has been shown to have both stimulatory and inhibitory effects on various mammalian cells, depending on the concentration used. Whether these cytotoxic effects can be used in the clinical treatment of tumors remains to be established. Here, we evaluated the effects of fusarochromanone on the growth of human melanoma cells both in vitro and in vivo. In vitro, low concentrations (0.1-1 nmol/l) of fusarochromanone were found to be cytotoxic to many melanoma cell lines. In contrast, growth of normal melanocytes was inhibited only at much higher fusarochromanone concentrations (100-200 nmol/l). In vivo, the growth of melanoma cells implanted subcutaneously in immuno-compromised mice was significantly (P<0.05) reduced by daily administration of fusarochromanone. Immunohistological analyses indicated a significant (P<0.05) increase in the expression of active caspase-3 in tumor masses of mice treated with fusarochromanone, compared with controls. Together, these observations show that fusarochromanone increased apoptosis of tumor cells and reduced tumor growth in vivo. Therefore, the effects of fusarochromanone warrant further investigation as an adjuvant molecule to prevent growth and recurrence of melanomas.
Collapse
Affiliation(s)
- Didier Dréau
- Department of Biology, University of North Carolina-Charlotte , Charlotte, North Carolina 28223, USA.
| | | | | | | | | | | |
Collapse
|
8
|
Gabri MR, Mazorra Z, Ripoll GV, Mesa C, Fernandez LE, Gomez DE, Alonso DF. Complete antitumor protection by perioperative immunization with GM3/VSSP vaccine in a preclinical mouse melanoma model. Clin Cancer Res 2007; 12:7092-8. [PMID: 17145833 DOI: 10.1158/1078-0432.ccr-06-1075] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
PURPOSE The GM3/VSSP vaccine is composed of very small sized proteoliposomes resulting from the hydrophobic conjugation of GM3 ganglioside with membrane proteins from Neisseria meningitidis. Previously, we showed that preventive vaccination with GM3/VSSP induces a specific antitumor response and elicits the rejection of syngeneic GM3-positive melanoma cells in immunized mice. Our aim was to explore the antitumor properties of perioperative GM3/VSSP vaccination in a preclinical mouse model. EXPERIMENTAL DESIGN The highly metastatic B16F10 mouse melanoma was used to investigate perioperative vaccination with GM3/VSSP. The vaccine was administered i.m. in doses of 120 microg emulsified with the adjuvant Montanide ISA 51 at weekly or biweekly intervals, and s.c. tumors were excised 25 to 31 days after tumor cell implantation. The persistence of antitumor protection and dose dependency was also examined in preimmunized animals. To evaluate the immune performance of tumor-bearing and tumor-operated mice, ovoalbumin-specific delayed-type hypersensitivity, cytokine secretion, and cell proliferation responses were studied. RESULTS Surgical excision of B16F10 tumors improved survival, and perioperative immunization with four biweekly GM3/VSSP doses yielded survival for all animals (P = 0.04; log-rank test). Mice showed neither local recurrence nor lung metastasis at the end of the experiment. An impairment of CD4(+) T-cell responses was observed in tumor-bearing animals measured as neoantigen-specific delayed-type hypersensitivity, with a significant recovery after surgery. A strong interleukin-4 secretion was induced in B16F10-operated mice, whereas IFN-gamma remained unaffected. CONCLUSION Preclinical evidence suggests that GM3/VSSP vaccine might have therapeutic potential to induce antitumor immunity in patients with minimal residual disease after surgery, thereby preventing or prolonging the time to recurrence.
Collapse
Affiliation(s)
- Mariano R Gabri
- Laboratory of Molecular Oncology, Department of Science and Technology, Quilmes National University, Buenos Aires, Argentina.
| | | | | | | | | | | | | |
Collapse
|
9
|
Zhang S, Wang Q, Miao B. Review: Dendritic Cell-Based Vaccine in the Treatment of Patients with Advanced Melanoma. Cancer Biother Radiopharm 2007; 22:501-7. [PMID: 17803444 DOI: 10.1089/cbr.2007.354] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Traditionally, immunology is mainly about the study of the immune response against foreign antigens, such as bacteria and viruses. Accordingly, tumor cells expressing alien or altered antigens make the attractive targets against which cancer immunology is initiated. However, recent comprehensive studies demonstrated that most prevalent antigens recognized by our immune system in cancer are those shared, nonmutated self-antigens expressed also by normal tissue cells. Thus, how to break the self-tolerance and avoid the concomitant autoimmunity remain the two challenges in cancer immunology. Dendritic cells (DCs) are the most effective antigen-presenting cells. They are capable of capturing, processing, and presenting antigens to T- and B-cells. This feature targets dendritic cells as the ideal candidates for breaking self-tolerance in cancer immunology. Clinical trials have demonstrated that dendritic cells are effective messengers. They circulate around the body and stimulate cytotoxic T-lymphocytes to clear tumor cells. Vaccination with DCs led to a clinical response in patients with melanoma, specifically those without significant autoimmunity. In this paper, we will examine the strategies and efficacies of DC-based vaccinations in the treatment of patients with melanoma.
Collapse
Affiliation(s)
- Sheng Zhang
- Department of Medical Oncology, First People's Hospital, Shanghai Jiaotong University, Shanghai, China.
| | | | | |
Collapse
|
10
|
de Vries E, Houterman S, Janssen-Heijnen MLG, Nijsten T, van de Schans SAM, Eggermont AMM, Coebergh JWW. Up-to-date survival estimates and historical trends of cutaneous malignant melanoma in the south-east of The Netherlands. Ann Oncol 2007; 18:1110-6. [PMID: 17434898 DOI: 10.1093/annonc/mdm087] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND We present survival outcomes of patients registered in the Dutch population-based Eindhoven Cancer Registry (ECR). PATIENTS AND METHODS Data on patients diagnosed with a melanoma between 1980 and 2002 were obtained from the ECR. Data on vital status up to 1 January 2005 were obtained, up-to-date survival rates were calculated using period analysis. Multivariate analyses were carried out using Cox proportional hazards model. RESULTS Ten-year crude survival rates were 82% for women and 60% for men (P < 0.05). Thin melanomas (Breslow thickness <or= 2.0 mm) had 5-year crude survival rates >74%, for melanomas >4.0 mm these rates were <65% (P < 0.05). In the early 1980s, 5-year relative survival rates were 84% and 62% for young (<60 years) women and men, and 66% and 69%, respectively, for the elderly (aged 60+). In the period 2000-2002, these rates had improved to >90% for females and to >72% for males. Multivariate analyses showed increased hazard ratios with increasing age and Breslow thickness, being male, having a melanoma on the trunk or unknown sites and having a nodular melanoma. CONCLUSIONS Despite the absence of improvements in treatment options for melanoma, survival improved significantly, except for elderly males.
Collapse
Affiliation(s)
- E de Vries
- Department of Public Health, Erasmus MC University Medical Centre Rotterdam, Rotterdam, The Netherlands.
| | | | | | | | | | | | | |
Collapse
|